Expression of metallothionein‐1 and metallothionein‐2 as a prognostic marker in hepatocellular carcinoma

Park, Yangsoon; Yu, Eunsil

doi:10.1111/jgh.12261

Cited by 25 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Later on, the expression of MT1/2 was evaluated immunohistochemically in tissue microarrays containing samples from HCCs, adjacent noncancerous livers, and normal livers [56]. This study demonstrated the loss of nuclear and cytoplasmic expression of MT1/2 in HCC compared with adjacent noncancerous liver tissues and that the loss of nuclear MT1/2 expression is an independent prognostic indicator of poor recurrence-free survival and overall survival in patients with HCC [56].…”

Section: Hepatic Tumoursmentioning

confidence: 99%

See 1 more Smart Citation

Microarray analysis of metallothioneins in human diseases—A review

Křížková

Kępińska

Emri

et al. 2016

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1 Microarray analysis of metallothioneins in human diseases AbstractMetallothioneins (MTs), low molecular mass cysteine-rich proteins, which are able to bind up to 20 monovalent and up to 7 divalent heavy metal ions are widely studied due to their functions in detoxification of metals, scavenging free radicals and cells protection against the oxidative stress. It was found that the loss of the protective effects of MT leads to an escalation of pathogenic processes and carcinogenesis. 3The most extensive area is MTs expression for oncological applications, where the information about gene patterns is helpful for the identification biological function, resistance to drugs and creating the correct chemotherapy. In other medical applications the effect of oxidative stress to cell lines exposed to heavy metals and hydrogen peroxide is studied as well as influence of drugs and cytokines on MTs expression and MTs expression in the adiposetissue. The precise detection of low metallothionein concentrations and its isoforms is necessary to understand the connection between quantity and isoforms of MTs to size, localization and type of cancer. This information is necessary for well-timed therapy and increase the chance to survival. Microarray chips appear as good possibility for finding all information about expression of MTs genes and isoforms not only in cancer, but also in other diseases, especially diabetes, obesity, cardiovascular diseases, ageing, osteoporosis, psychiatric disorders and as the effects of toxic drugs and pollutants, which is discussed in this review. List of abbreviations:HCC -hepatocellular carcinoma, HFD -high fat diet, MMP -matrix metalloproteinase, MT -metallothionein, MTF -metal transcription factor, MRE -metal responsive element, ROS -reactive oxygen species.

show abstract

Section: Hepatic Tumoursmentioning

confidence: 99%

“…This study demonstrated the loss of nuclear and cytoplasmic expression of MT1/2 in HCC compared with adjacent noncancerous liver tissues and that the loss of nuclear MT1/2 expression is an independent prognostic indicator of poor recurrence-free survival and overall survival in patients with HCC [56].…”

Section: Hepatic Tumoursmentioning

confidence: 99%

Microarray analysis of metallothioneins in human diseases—A review

Křížková

Kępińska

Emri

et al. 2016

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

show abstract

“…31 In fact, human HCC tumor cells show significantly higher loss of nuclear and cytoplasmic MT expression than in noncancerous livers and MT expression loss may be related to poorer overall survival prognosis. 32 Patients with Wilson's disease and HCC from the published literature were recently collated: 86% were male, mean age was 42 years (range 12-73 years), and all were cirrhotic except one. 33,34 Further analysis of the clinical details from those 28 patients revealed that a hepatic copper quantification was determined in 16 patients and was above the normal range in 14 of 16 patients (88%).…”

Section: Discussionmentioning

confidence: 99%

Beneath the Copper—Pediatric Wilson's Disease Cirrhosis and Hepatocellular Carcinoma: A Case Report with Literature Review

2015

View full text Add to dashboard Cite

Primary hepatic malignancies are uncommon in pediatrics. Tumors such as hepatocellular carcinoma (HCC) develop typically in the setting of chronic liver disease. The incidence of HCC in Wilson's disease-related cirrhosis is disproportionately lower than in many other forms of end-stage liver disease. A preadolescent girl presented with Wilson's disease cirrhosis and a HCC requiring orthotopic liver transplantation. This case highlights the need to consider hepatic malignancies even in young Wilson's disease patients. Pediatric Wilson's disease and the hepatic tumor literature are reviewed.

show abstract

“…In contrast to many other cancers, in HCC tissues, MT-1 and MT-2 expression, evaluated by microarray, has been found to be reduced, a fact correlated with a poor prognosis [39] . Additionally, reduced expression levels have been correlated to higher HCC grade and tumor vascular invasion [40] . Together these data indicate that the down-regulation of MT-1 and MT-2 may be undertaken as a poor prognostic factor for HCC patients.…”

Section: Metallothioneinsmentioning

confidence: 99%

Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials

Scaggiante

Kazemi

Pozzato

et al. 2014

WJG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related death. The difficulty to diagnose early cancer stages, the aggressive behaviors of HCC, and the poor effectiveness of therapeutic treatments, represent the reasons for the quite similar deaths per year and incidence number. Considering the fact that the diagnosis of HCC typically occurs in the advanced stages of the disease when the therapeutic options have only modest efficacy, the possibility to identify early diagnostic markers could be of significant benefit. So far, a large number of biomarkers have been associated to HCC progression and aggressiveness, but many of them turned out not to be of practical utility. This is the reason why active investigations are ongoing in this field. Given the huge amount of published works aimed at the identification of HCC biomarkers, in this review we mainly focused on the data published in the last year, with particular attention to the role of (1) molecular and biochemical cellular markers; (2) micro-interfering RNAs; (3) epigenetic variations; and (4) tumor stroma. It is worth mentioning that a significant number of the HCC markers described in the present review may be utilized also as targets for novel therapeutic approaches, indicating the tight relation between diagnosis and therapy. In conclusion, we believe that integrated researches among the different lines of investigation indicated above should represent the winning strategies to identify effective HCC markers and therapeutic targets.

show abstract

Expression of metallothionein‐1 and metallothionein‐2 as a prognostic marker in hepatocellular carcinoma

Abstract: The expression of MT-1 and MT-2 may play a role in HCC differentiation and carcinogenesis, and may predict prognosis in patients with HCC.

Cited by 25 publications

References 39 publications

Microarray analysis of metallothioneins in human diseases—A review

Microarray analysis of metallothioneins in human diseases—A review

Beneath the Copper—Pediatric Wilson's Disease Cirrhosis and Hepatocellular Carcinoma: A Case Report with Literature Review

Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials

Contact Info

Product

Resources

About